Skip to main content

Table 2 Incidence of transfusions

From: Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus ≥10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial

 

Baseline Hemoglobin < 10 g/dL

Baseline Hemoglobin ≥10 g/dL

 

Darbepoetin alfa 500 mcg Q3W

N = 176

Darbepoetin alfa 2.25 mcg/kg QW

N = 175

Difference

(Q3W-QW)

Darbepoetin alfa 500 mcg Q3W

N = 177

Darbepoetin alfa 2.25 mcg/kg QW

N = 177

Difference

(Q3W-QW)

Week 5 to EOTP K-M percent (95% CI) [N]

36 (28 to 43) [164]

41 (33 to 49) [167]

-5.1 (-16.1 to 5.9)

14 (7 to 20) [171]

21 (14 to 29) [170]

-7.3(-17.3 to 2.8)

Week 1 to EOTP K-M percent (95% CI)

44 (37 to 52)

47 (39 to 54)

-2.3 (-13.2 to 8.6)

14 (8 to 21)

26 (18 to 33)

-11.3 (-21.4 to -1.2)

  1. Q3W = every three weeks; QW = weekly; EOTP = end of the treatment period (defined as the earlier of day 109 or end of study); K-M = Kaplan-Meier